Moderna Stock Sinks. The Puzzling Reason Its Flu Vaccine Was Rejected.

Yahoo Finance Published Updated Economy
Sign in to save

Why it matters

Moderna's stock has declined due to the FDA's rejection of its application for a new seasonal flu vaccine, leaving investors puzzled about the reason behind the decision.

Expected market reaction

Bearish Confidence 90% How confidence is read Horizon: Short term Impact: Moderate

Market impact analysis based on bearish sentiment with 90% confidence.

Evidence trail

Evidence
Source Yahoo Finance
Claim Moderna Stock Sinks. The Puzzling Reason Its Flu Vaccine Was Rejected.
AI inference Bearish · 90%
Generated 2026-02-11 13:24

AI provenance

Analysed by Llama 3.1 8B Instant (Groq) Methodology v1.0 Generated
Technical identifiers
Provider tag
groq-llama-3.1-8b-instant
Analysis version
groq-llama-3.1-8b-instant
Article id
44494

Original source

The vaccine maker says the Food and Drug Administration has refused to review its application to sell a new seasonal flu vaccine.

Read the full article on Yahoo Finance

Original article published by Yahoo Finance on February 11, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage